Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | RANBP3 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
mRNA | PRR12 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-07 |
mRNA | SRSF3 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
mRNA | PHF10 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
mRNA | ARHGDIG | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-07 |
mRNA | NAA16 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
mRNA | BSN | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
mRNA | BCLAF1 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-07 |
mRNA | CCAR2 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-07 |
mRNA | CTSA | CTRPv2 | pan-cancer | AAC | -0.18 | 3e-07 |